Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients by E. Venturelli et al.
RESEARCH ARTICLE Open Access
Observational study on the prognostic
value of testosterone and adiposity in
postmenopausal estrogen receptor positive
breast cancer patients
Elisabetta Venturelli1*† , Annalisa Orenti†, Aline S. C. Fabricio3, Giulia Garrone1, Roberto Agresti4, Biagio Paolini5,
Chiara Bonini5, Massimo Gion3, Franco Berrino1, Christine Desmedt6, Danila Coradini2† and Elia Biganzoli2,7†
Abstract
Background: Despite the clear endocrine-metabolic relationship between androgenic activity and adiposity, the
role of androgens in breast cancer prognosis according to patient’s adiposity is scarcely explored. Here, we aimed
at investigating the prognostic value of circulating testosterone in association with patient’s body mass index (BMI).
Methods: Circulating testosterone and BMI were evaluated at breast cancer diagnosis in 460 estrogen receptor (ER)-
positive postmenopausal patients. Local relapse, distant metastasi(e)s and contralateral breast cancer were considered
recurrence events. The Kruskal-Wallis test was performed to evaluate if testosterone levels differed within subgroups of
categorical tumour characteristics. The Cox proportional hazard regression model was fitted to estimate the impact of
standard prognostic factors on relapse-specific hazard ratio (HR). After backward selection, a model including continuous
testosterone level, BMI categories (< 25, normal-weight; =25–30, overweight; ≥30 kg/m2, obese), tumour size and lymph
nodes number was fitted. Furthermore, Cox models provided the relapse-specific HRs for median, third quartile and 95th
percentile compared to the first quartile of testosterone levels, stratified by BMI categories.
Results: During a median follow up of 6.3 years, 45 patients relapsed. Testosterone levels significantly increased across
BMI categories (p = 0.001). Both circulating testosterone and BMI were positively associated with disease free survival (p =
0.005 and p = 0.021, respectively). A significant interaction was found between testosterone and BMI (p = 0.006). For
normal-weight women, testosterone concentration around median (0.403 ng/mL) or third quartile (0.532 ng/mL) showed
a high significant HR of relapse (5.52; 95% CI:1.65–18.49 and 4.55; 95% CI:1.09–18.98, respectively). Overweight patients
showed increased HR at increasing testosterone levels, reaching a significant high HR (4.68; 95% CI:1.39–15.70) for
testosterone values of 0.782 ng/mL (95th percentile). For obese patients HR decreased (not significantly) at increased
testosterone concentrations, explaining the interaction between testosterone levels and BMI categories.
Conclusions: In ER-positive postmenopausal breast cancer patients, high testosterone levels are associated with worse
prognosis in normal-weight and overweight women, whereas in obese seems to be associated with a better outcome.
Although the results require further validation, they suggest that assessment of circulating testosterone and BMI could help
to identify postmenopausal ER-positive patients at higher risk of relapse and potentially open new therapeutic strategies.
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Background
The role of androgens in breast cancer is an old debated
topic. While many aspects still remain unclear, several
studies consistently demonstrated that high levels of tes-
tosterone are associated with an increased risk of develop-
ing breast cancer, especially in ER-positive tumours [1–7].
Conversely, few studies have investigated the potential
prognostic value of testosterone [8–11]. In particular, pre-
vious studies from our group showed that elevated urinary
levels of testosterone were associated with a worse out-
come [8]. More recently, prospective studies have pro-
vided evidence for an increased rate of progression in
postmenopausal patients with high circulating levels of
testosterone [9–11]. It is known that, in postmenopausal
women, adiposity― especially abdominal fatness― is as-
sociated with high levels of circulating testosterone and
estradiol. A positive association has also been described
between sex hormones levels and Body Mass Index (BMI),
the parameter used as proxy for adiposity [12–14]. In-
creased BMI has, in turn, been associated with both onset
and progression of postmenopausal breast cancer patients
in particular with ER-positive tumours [15–17]. After
menopause, with the decline of the ovarian production of
estrogens and with the tendency of women to gain weight,
a concomitant presence of high androgenic activity can
trigger a series of endocrine-metabolic disorders including
sex hormones imbalance, insulin resistance, metabolic
syndrome and inflammatory response [18, 19], possibly
providing a suitable milieu for the growth of breast cancer
[20]. Several evidences suggest the presence of a coordin-
ate mechanism whereby, when estrogens lessen, testoster-
one promotes a redistribution of fat deposits that
preferentially accumulate in the abdomen [21, 22]. This
excess of visceral fat, known as central obesity, plays a
relevant role in favoring the onset of insulin resistance
and related dismetabolism, such as hyperinsulinemia,
IGF-I hyper-production and metabolic syndrome [18, 19].
An excessive insulin production also stimulates the syn-
thesis of androgens by the ovary and inhibits the hepatic
production of sex hormone-binding globulin (SHBG), the
protein that carries sex hormones through the blood-
stream [23, 24]. The result is a further increase in total
and free testosterone levels, which in turn, on the one
hand favor higher estradiol bioavailability by its
aromatization at adipose tissue levels [25] and by binding
SHBG with a greater affinity than estrogens [26], and on
the other hand strengthen the progression of insulin re-
sistance by continuing to promote the visceral fat accumu-
lation [21, 22]. This endocrine-metabolic loop favored by
the advent of menopause, may particularly be harmful for
recurrences of hormone-dependent breast cancer, i.e., tu-
mours expressing ER, since the high availability of sex
hormones and growth factors acts as a strong stimulus for
tumour growth [27, 28].
Despite the clear interrelationship between adiposity
and androgenic activity, studies specifically aimed at in-
vestigating the impact of this relationship on prognosis
of postmenopausal ER-positive breast cancer patients
are lacking. Therefore, in the present observational
retrospective study we investigated the prognostic role
of testosterone circulating levels as a function of pa-
tient’s BMI, in an institutional series of consecutive post-
menopausal women with ER-positive tumours.
Methods
Patients
This was an observational retrospective study focusing on
the first consecutive 592 eligible postmenopausal patients
recruited at Fondazione IRCSS Istituto Nazionale Tumori
of Milan (INT) from December 2003 to December 2006
in the TPM (Testosterone Prognosis, Mammary cancer)
cohort and whose follow-up ended at December 2012.
The study was approved by the INT Scientific and Ethical
Committee and written informed consent was obtained
from all included patients. Clinical and pathological infor-
mation (self-reported weight and height- recorded during
first clinic visit), date and type of surgery, histology, TNM
stage, tumour grade, immuno-histochemical evaluation of
ER and Progesterone Receptor (PR) status, and HER2
overexpression), as well as follow-up information (radio-
therapy, adjuvant therapy, date of last control, date and
site of breast cancer recurrence, presence of a primary
non-breast cancer, life-status, and date and cause of
death), obtained from medical records, were retrieved
from the TPM database. Extensively presented elsewhere
[14, 29, 30], the whole TPM cohort includes patients with
a primary breast cancer surgically treated at the Breast
Surgery Unit of the INT from December 2003 to March
2011. Inclusion criterion was having histologically con-
firmed non-metastatic breast carcinoma (any T, any N,
and M0). Exclusion criteria included the presence of a
nonepithelial cancer, a previous cancer diagnosis (except
for in situ cervical cancer or non-melanoma skin cancer),
and the treatment with neoadjuvant chemo- or hormone
therapy. Before surgery, patients provided a fasting blood
sample which was processed to obtain serum, subdivided
into aliquots and stored at − 80 °C until use.
The expression of androgen receptor (AR) in tumour
tissue was evaluated by tissue microarrays as described
elsewhere [30].
TPM-postmenopausal patients were treated according
to international guidelines for breast cancer management
[31]. Subjects were routinely followed-up from the entry
to the study to any of the following events: breast cancer
recurrence, other non-breast primary cancer, death or
scheduled end of follow-up. Information about vital status
of patients who had discontinued their regular control at
our institution was obtained through telephone interviews
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with patients or their next of kin. Interviews were carried
out by expert trained personnel in accordance with a pre-
defined protocol. Of the 592 initial postmenopausal breast
cancer women recruited in the TPM cohort, 37 were
excluded because they proved to fall outside the recruit-
ment criteria, 19 violated postmenopausal criteria (last
menstruation ≥12 months before enrolment, bilateral oo-
phorectomy or hysterectomy without oophorectomy or
monolateral oophorectomy and ≥ 50 y old and estradiol
≤30 pg/mL); 10 were excluded because they stopped hor-
mone replacement therapy only 3 months before recruit-
ment; 5 had previous cancer diagnosis; 1 had already
metastatic disease and 2 received neoadjuvant therapy. Of
the 555 remaining in the cohort, 460 were identified as
ER-positive and represent the current study population
(Additional file 1: Figure S1).
Testosterone assay
Baseline serum testosterone levels were evaluated in du-
plicate using RIA commercial kits (Orion Diagnostica,
Espoo, Finland) according to the manufacturer’s instruc-
tions. The kit detection limit was 0.03 ng/mL. Interassay
coefficients of variation were 6.4 and 7.6% for mean tes-
tosterone titers of 0.359 and 0.455 ng/mL, respectively.
Statistical analysis
According to WHO recommendation (Report of a WHO
Expert Committee 1995) BMI was classified as < 25 (nor-
mal weight), =25–30 (overweight) and ≥ 30 kg/m2 (obese).
Only 5 women were mild underweight and were included
in the first BMI category. Tumour size was classified ac-
cording to pT categories, as pT1, pT2 and pT3-pT4,
tumour histology as IDC (Invasive Ductal Carcinoma), ILC
(Invasive Lobular Carcinoma), mixed IDC/ILC and other
histology; tumour grade as (G)1, G2 and G3; the number of
metastatic axillary lymph nodes (N) as =0, 1–2 and > 2.
Steroid receptor status was defined as positive when
the percentage of stained tumour cells was ≥10%, ≥10%
and ≥ 1% for ER, PR and AR, respectively [30]. Categor-
ical tumour characteristics were summarized by means
of counts and percentages and chi-square test was per-
formed to evaluate if tumour characteristics differed ac-
cording to BMI categories. To assess if testosterone
levels differed within subgroups of categorical variables,
boxplots of testosterone levels according the catego-
rized variables were drawn and non-parametric
Kruskal-Wallis tests were performed. Time from sur-
gery to first relapse was used in the estimation of dis-
ease free survival (DFS). The events used as end points
in the determination of DFS included first local recur-
rence of disease, axillary and distant metastases, contra-
lateral breast cancer. Patients who died without
experiencing a breast cancer relapse previously were
censored in the analysis of DFS.
Cox proportional hazard regression model was fitted to
estimate the impact of different standard breast cancer
prognostic factors as covariates on relapse-specific hazard.
The initial model included steroid hormone status (PR
and AR), tumour characteristics (histology, size, grade,
number of metastatic lymph nodes and HER2 status), and
patient characteristics (age, testosterone level, and BMI
categories) as independent covariates. The proportional
hazard assumption of the Cox model was also assessed.
First, models were developed to identify variables most
predictive of events, using a stepwise approach employing
the most significant predictors. After backward selection,
a model including only testosterone level as a continuous
variable, BMI category, tumour size and the number of
metastatic lymph nodes was fitted. To better interpolate
smoothing effect of continuous covariates, nonlinear effect
of testosterone was modeled by means of a cubic re-
stricted spline with 3 knots [32]. The interaction between
testosterone and BMI categories was considered to model
the differential testosterone effect over different BMI clas-
ses. Thus, the final Cox model included continuous testos-
terone level (using a cubic spline with 3 knots), categorical
BMI, the interaction term between testosterone and BMI,
and tumour size and metastatic axillary lymph as adjust-
ing covariates.
A plot of testosterone relapse-specific hazard ratio (HR)
in the different BMI categories was drawn; the first quar-
tile of circulating testosterone in the whole sample was
taken as reference value. Accordingly, within the different
BMI categories, numerical estimates of relapse-specific
HRs were provided for three values of testosterone level,
corresponding to median, third quartile and 95th percent-
ile with respect to the first quartile of testosterone levels.
Pertinent 95% confidence intervals were also provided. All
p-values refer to two-sided statistical tests with p < 0.05
considered statistically significant. The analyses were per-
formed using R statistical software v.3.3.2 with survival
and rms packages.
Results
Serum testosterone and tumour characteristics
Table 1 shows the baseline characteristics of the 460
ER-positive postmenopausal women as a whole and
according to BMI categories. Out of 460 ER-positive
patients, 195 women had BMI < 25, 141 BMI = 25–30,
78 with BMI ≥ 30, and 46 unknown BMI. The median
value of testosterone in serum of ER-positive patients
was 0.403 ng/mL (1st and 3rd quartile: 0.278,
0.532 ng/mL). The associations between testosterone
levels and the tumour characteristics found in the ori-
ginal 592 TPM-postmenopausal women have been ex-
tensively described in three previously published
studies [14, 29, 30], and were substantially confirmed
in the current series of 460 ER-positive patients. In
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particular, it was confirmed that testosterone levels
significantly increased across BMI categories (p =
0.001; Fig. 1). Significant increase in the levels of the
androgen was also confirmed for increasing tumours
size (p = 0.012). No significant associations were found
for the remaining tumour characteristics (histology,
tumour grade, axillary nodal status, AR, PR and
HER2 status; Additional file 2: Figure S2).
Table 1 Patient and tumour characteristics of ER-positive postmenopausal breast cancer patients as whole and according to BMI
categories
Total cases
N = 460
BMI < 25
N = 195
BMI 25–30
N = 141
BMI ≥30
N = 78
p-valuea
Histology
IDC 350 (76.9%) 135 (71.1%) 113 (80.1%) 65 (83.3%) 0.132
IDC + ILC 42 (9.2%) 19 (10.0%) 12 (8.5%) 6 (7.7%)
ILC 63 (13.8%) 36 (18.9%) 16 (11.3%) 7 (9.0%)
Other 5 5 0 0
Tumour size
pT1 306 (67.1%) 137 (71.7%) 92 (65.2%) 46 (59.0%) 0.167
pT2 121 (26.5%) 41 (21.5%) 42 (29.8%) 24 (30.8%)
pT3-pT4 29 (6.4%) 13 (6.8%) 7 (5.0%) 8 (10.3%)
NA 4 4 0 0
Tumour grade
G1 35 (7.7%) 18 (9.4%) 9 (6.4%) 4 (5.1%) 0.166
G2 293 (64.4%) 129 (67.2%) 82 (58.6%) 51 (65.4%)
G3 127 (27.9%) 45 (23.4%) 49 (35.0%) 23 (29.5%)
NA 5 3 1 0
Nodal status
Negative 288 (64.3%) 122 (64.2%) 83 (61.5%) 44 (57.1%) 0.689
Positive (1–2) 88 (19.6%) 34 (17.9%) 31 (23.0%) 18 (23.4%)
Positive (> 2) 72 (16.1%) 34 (17.9%) 21 (15.6%) 15 (19.5%)
NA 12 5 6 1
Progesterone receptor status
Negative 103 (22.4%) 52 (26.7%) 24 (17.0%) 11 (14.1%) 0.025
Positive 357 (77.6%) 143 (73.3%) 117 (83.0%) 67 (85.9%)
Androgen receptor status
Negative 37 (8.5%) 18 (9.9%) 15 (10.9%) 2 (2.7%) 0.099
Positive < 60% 162 (37.1%) 70 (38.5%) 50 (36.5%) 22 (29.7%)
Positive ≥60% 238 (54.5%) 94 (51.6%) 72 (52.6%) 50 (67.6%)
NA 23 13 4 4
HER2 status
Negative 176 (55.5%) 78 (56.5%) 51 (51.0%) 27 (56.2%) 0.520
Positive 2+ 90 (28.4%) 42 (30.4%) 28 (28.0%) 15 (31.2%)
Positive 3+ 51 (16.1%) 18 (13%) 21 (21.0%) 6 (12.5%)
NA 143 57 41 30
Endocrine therapy
No 30 (6.5%) 14 (7.2%) 6 (4.3%) 5 (6.4%) 0.543
Yes 429 (93.5%) 181 (92.8%) 134 (95.7%) 73 (93.6%)
NA 1 0 1 0
aAll p-values were evaluated excluding NA category or Other category for Histology variable
ER Estrogen Receptor, IDC Invasive Ductal Carcinoma, ILC Invasive Lobular Carcinoma, NA Not Available data
Venturelli et al. BMC Cancer  (2018) 18:651 Page 4 of 9
Serum testosterone, BMI, and disease-free survival
During a median follow up of 6.3 years (interquartile
range = 5.5–7.3 years), 45 patients experienced breast can-
cer recurrence within 7 years of follow-up. In particular, re-
lapse occurred in 18 women with BMI < 25, 14 with BMI
25–30, 11 with BMI ≥ 30, and 2 with unknown BMI. Out
of 460 ER-positive postmenopausal women, 31 died: 8 be-
cause of progressive disease and 23 for other causes than
cancer. Patients who died of breast cancer and previously
experienced a cancer relapse were already included as
events in DFS.
Fitting the final Cox model, it emerged that
relapse-specific hazard was significantly associated with cir-
culating levels of testosterone (p= 0.005), the latter having a
significant nonlinear effect (p= 0.042), as well as with BMI
(p = 0.021), as expected, with metastatic axillary lymph
nodes (p = 0.046), and with tumour size, even though non
significantly (p = 0.061). Moreover, the Cox model showed
that there is a significant interaction between testosterone
levels and BMI categories (p = 0.006), indicating a different
impact of testosterone level on DFS and consequently on
relapse-specific hazard, among the three BMI categories.
Considering the significant interaction between testos-
terone levels and BMI, relapse specific hazard as a func-
tion of continuous androgen levels have to be considered
separately for the three BMI groups.
The corresponding HRs associated with continuous
testosterone levels within the three BMI classes are plot-
ted in Fig. 2 considering the first quartile of circulating
testosterone (0.278 ng/mL) as reference value. Accord-
ingly, Table 2 reports for each BMI category, the numer-
ical values of HR plotted in Fig. 2, for three specific
values of testosterone level: 0.403 ng/mL (corresponding
to the median), 0.532 ng/mL (corresponding to the third
quartile) and 0.782 ng/mL (corresponding to the 95%
percentile), with respect to 0.278 ng/mL, which corre-
sponds to the first quartile of testosterone.
In normal-weight women, the risk of relapse showed a
bell-shape course with higher risk of relapse for levels of
testosterone around the median value and lower risk of re-
lapse for low and high testosterone levels (Fig. 2). Women
with a testosterone concentration around the median
value (0.403 ng/mL) or third quartile (0.532 ng/mL) had
high and significant HR of relapse (5.52; 95% CI: 1.65–
18.49 and 4.55; 95% CI: 1.09–18.98, respectively), com-
pared to women with a low testosterone concentration
(0.278 ng/mL, first quartile, Table 2), whereas the estima-
tion of the HRs for testosterone concentration higher than
third quartile showed decrease/stabilization of HRs with a
wide statistical uncertainty (Fig. 2 and Table 2).
In overweight patients the risk of relapse increased
(1.64; 95% CI: 0.69–3.91, 2.45; 95% CI: 0.75–8.02 and
4.68; 95% CI: 1.39–15.70) at increasing levels of testos-
terone (0.403 ng/mL, 0.523 ng/mL and 0.782 ng/mL, re-
spectively versus 0.278 ng/mL) (Fig. 2 and Table 2).
On the contrary, an inverse relationship between tes-
tosterone levels and risk of relapse was found in obese
patients. In this BMI group, there was a non-significant
trend towards decrease in the risk of relapse at increas-
ing levels of testosterone (Fig. 2 and Table 2).
Discussion
In the present study we examined the prognostic role of
circulating testosterone levels, according to BMI as a
proxy of adiposity, in a cohort of postmenopausal pa-
tients with ER-positive breast cancer.
Fig. 1 Boxplots of circulating levels of testosterone (ng/mL) according to body mass index (BMI) and tumour size (pT) of ER-positive
postmenopausal breast cancer patientsNumber and percentage of patients in each group are reported and p-values are given. The bar inside the
box is the median value and the box upper and lower dimensions define the inter-quartile range.
Venturelli et al. BMC Cancer  (2018) 18:651 Page 5 of 9
Our main findings confirmed that serum testosterone
measured at diagnosis is an important prognostic factor
for ER-positive breast cancer [9–11]. The novelty of this
work resides however in the demonstration of a different
impact of circulating testosterone on the risk of relapse,
depending on the BMI categories.
When we analyzed the relationship between circulating
testosterone, BMI, and risk of relapse we observed an inter-
esting and statistically significant interaction. Although our
data showed a certain degree of statistical uncertainty due
to sample size, we found that in normal-weight and over-
weight patients the HRs increased with increasing testoster-
one levels until about the median value. Thereafter, the two
BMI categories showed a rather different behavior: over-
weight patients had a further increase in the hazard of re-
lapse as testosterone increased, whereas according to the
confidence intervals, normal-weight patients showed no
evidence of increase, but a decrease/stabilization of HRs for
higher testosterone levels. Conversely, obese patients ap-
peared to be characterized by a risk of relapse that
decreased when testosterone levels increased, suggesting
that the presence of high testosterone levels could reduce
the high risk of recurrence typical of obese women. The ob-
servation that high levels of testosterone are associated with
high HRs of relapse in normal-weight and overweight
women, but not in obese patients, raises interesting ques-
tions about the relationship between adiposity, circulating
testosterone and endocrine treatment of breast cancer.
From a mechanistic point of view, the influence of
testosterone on tumour growth is presumably different in
the onset compared to the progression of the disease.
While in the onset of breast cancer the androgenic
conversion into estrogen is the most plausible mechanism
involved in tumour growth by estrogen/ER signalling [33,
34], the same path is unlikely in disease progression. Ac-
cording to international guidelines for breast cancer man-
agement [31], most of the ER-positive patients are
submitted to hormone treatment aimed to block the
ER-mediated proliferative events when tamoxifen is given,
or to inhibit androgen-to-estrogen conversion [34, 35]
when aromatase inhibitors are used. It is, therefore, con-
ceivable that in ER-positive normal-weight or overweight
patients undergoing endocrine treatment, the high levels of
testosterone mainly affect tumour relapse through an alter-
native estrogen/ER signaling, likely by androgen/AR prolif-
erative axis or by favoring proliferation along growth
factors pathway [35, 36]. Although our study is too small to
provide association between high levels of circulating tes-
tosterone, AR status, BMI and prognosis, recent preclinical
researches showed that AR-overexpression is involved in
the mechanism of resistance to endocrine-therapy either
with tamoxifen [37, 38] or aromatase inhibitors [39, 40]. In
a tumour environment depleted of estrogen or where estro-
genic action is inhibited, AR-overexpressing breast cancer
cells may acquire alternative proliferation mechanisms
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Fig. 2 Estimated effect of circulating levels of testosterone on breast cancer relapse in the different BMI groups of ER-positive
postmenopausal breast cancer patients according to Cox proportional hazard regression model for DFS, using testosterone levels as a
continuous variable, BMI category, interaction terms between testosterone and BMI, with tumour size and number of metastatic lymph
nodes as adjusting covariates. Relapse-specific hazard ratios with pertinent 95% confidence intervals are plotted. First quartile of
testosterone level (0.278 ng/mL) is the reference value
Table 2 Hazard ratio (HR) of relapse of ER-positive postmenopausal
breast cancer patients for median (0.403 ng/mL), third quartile
(0.532 ng/mL) and 95% percentile (0.782 ng/mL) with respect to
the first quartile (0.278 ng/mL) of testosterone levels, according to
BMI groups
Testosteronea
level (ng/mL)
BMI < 25 BMI 25–30 BMI ≥30
HRb (95% CI) HRb (95% CI) HRb (95% CI)
0.403 versus 0.278 5.52 (1.65–18.49) 1.64 (0.69–3.91) 0.68 (0.40–1.14)
0.532 versus 0.278 4.55 (1.09–18.98) 2.45 (0.75–8.02) 0.61 (0.31–1.20)
0.782 versus 0.278 0.25 (0.01–6.55) 4.68 (1.39–15.70) 0.75 (0.22–2.55)
aTestosterone levels were included as a continuous variable into the model
bTumour size and the number of metastatic lymph nodes were included in the
Cox proportional hazard regression model as adjusting covariates. In
parenthesis, pertinent 95% confidence interval
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through AR-dependent intracellular ER-signalling [37–40].
Interestingly, in the group of our ER-positive TPM-patients
characterized by BMI < 25, no AR expression (18 patients)
or testosterone levels lower than the first quartile value (<
0.278 ng/mL, 56 patients), no relapse was observed (data
not shown). This observation is consistent with the above
hypothesis, i.e., in the absence of AR or in the presence of
very low testosterone levels, the androgen-driven resistance
mechanism would not trigger.
A further pathway of drug-resistance influenced by in-
creased androgenic activity and able to replace the estro-
gen/ER proliferative pathway may occur through the
insulin/IGFI axis [35, 36]. In fact, in presence of abdominal
fatness, high testosterone affects, in a mutual interaction,
the development of insulin resistance, a pathological condi-
tion linked to hyperinsulinemia and IGF-I over-production,
especially in a state of estrogen deficiency [18, 20, 41].
Regarding obese women, our data suggest that those
with high testosterone have a lower risk of progression
than obese women with low hormone levels. This last
association did not reach statistical significance; anyway
the interaction found between testosterone levels and
BMI classes indicates that testosterone affect positively
the prognosis of obese women compared to that of
normal-weight or overweight patients. To our know-
ledge, studies investigating this issue and with which to
compare our findings are lacking, and we believe that
these data deserve further in-depth studies on a larger
number of patients.
A limitation of the present study is that patients were not
stratified by type of endocrine treatment (i.e. tamoxifen or
aromatase inhibitor, AI). However, tamoxifen and AI are ex-
pected either to create a tumour environment poor in estro-
gen or to inactivate ER, thus blocking almost completely
the functioning of estrogen/ER axis [35, 36]. Therefore,
under both treatments, high testosterone levels may be in-
volved in the activation of alternative estrogen/ER-signal-
ling, through androgen-AR and/or growth factors pathways.
The common denominator is that, regardless of the drug
used, high testosterone levels may play an important role in
the drug resistance onset, ultimately leading to disease pro-
gression [37–40]. Nevertheless, aware of these implications,
we are planning to investigate this specific point in forth-
coming studies with expanded TPM-cohort sample size.
Conclusion
While the present findings need to be validated and further
refined according to the type of endocrine treatment re-
ceived, they suggest that an increased androgenic activity
not only plays an important role in the onset of breast can-
cer as demonstrated consistently in the literature [3–5], but
also impacts the prognosis of ER-positive breast cancer pa-
tients, according to patients adiposity. While increased tes-
tosterone levels are associated with worse prognosis in
normal-weight and overweight patients, increased levels
seemed to be associated with a better prognosis in obese
patients, although the results did not reach statistical sig-
nificance in the latter. Several mechanisms have been sug-
gested for explaining the association between increased
testosterone levels and worse prognosis [8, 33, 36–39]. The
most probable is that it acts as an aromatase substrate for
estrogen synthesis [25, 33, 34], but also may favor resistance
to hormonal treatment through alternative ER-signaling
[37–40], likely by AR-axis, and predisposing to the visceral
fat accumulation and to the endocrine-metabolic imbal-
ances associated with insulin resistance, which in turn me-
diate breast cancer growth [20–22].
Altogether, although the present results need to be fur-
ther validated, they suggest that the evaluation of circulat-
ing levels of testosterone in association to BMI assessment
at diagnosis may help to identify postmenopausal
ER-positive patients at higher risk of relapse and poten-
tially open new therapeutic strategies in breast cancer.
Additional files
Additional file 1: Figure S1. Workflow for the selection of TPM-ER-
positive postmenopausal breast cancer patients. Shows the workflow for
the selection of ER-positive postmenopausal breast cancer patients, start-
ing from the 592 initial women recruited consecutively in the TPM cohort
from December 2003 to December 2006, at Fondazione IRCSS Istituto
Nazionale Tumori of Milan. (PDF 42 kb)
Additional file 2: Figure S2. Boxplots of circulating level of testosterone
(ng/mL) according to tumour histology (IDC = Invasive Ductal Carcinoma;
ILC = Invasive Lobular Carcinoma), Grade (G), number of metastatic axillary
lymph Nodes (N), progesterone receptor (PR) and HER-2 status of ER-positive
postmenopausal breast cancer patients. Number and percentage of patients
in each group are reported and p-values are given. The bar inside the box is
the median value and the box upper and lower dimensions define the inter-
quartile range. Shows the boxplots of circulating level of testosterone (ng/mL)
according to the other tumour characteristics considered in the study (hist-
ology, tumour grade, axillary nodal status, PR and HER-2 status). On the whole,
the results did not indicate an association between circulating level of testos-
terone and unfavorable tumour characteristics as high tumour grade, axillary
involvement or HER2 overexpression. (PDF 22 kb)
Abbreviation
AR: Androgen Receptor; BMI: body mass index; ER: Estrogen Receptor;
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Carcinoma; IGF-I: Insulin-Like Growth Factor-I; ILC: Invasive Lobular
Carcinoma; INT: Fondazione IRCSS Istituto Nazionale Tumori of Milan;
PR: Progesterone Receptor; SHBG: Sex Hormone-Binding Globulin;
TPM: Testosterone Prognosis, Mammary cancer
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